Advertisement
Advertisement

CABA

CABA logo

Cabaletta Bio, Inc. Common Stock

2.56
USD
Sponsored
-0.19
-6.73%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

2.58

+0.02
+0.58%

CABA Earnings Reports

Positive Surprise Ratio

CABA beat 14 of 25 last estimates.

56%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.47
Implied change from Q3 25 (Revenue/ EPS)
--
/
+6.82%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-27.69%

Cabaletta Bio, Inc. Common Stock earnings per share and revenue

On Oct 27, 2025, CABA reported earnings of -0.44 USD per share (EPS) for Q3 25, beating the estimate of -0.48 USD, resulting in a 8.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.96% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.47 USD, with revenue projected to reach -- USD, implying an increase of 6.82% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Cabaletta Bio, Inc. Common Stock reported EPS of -$0.44, beating estimates by 8.6%, and revenue of $0.00, 0% as expectations.
The stock price moved up 12.96%, changed from $2.47 before the earnings release to $2.79 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 11 analysts, Cabaletta Bio, Inc. Common Stock is expected to report EPS of -$0.47 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement